SION

Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for cystic fibrosis patients. The company emerged from stealth mode and went public, focusing specifically on creating medicines that restore normal function to the defective protein responsible for cystic fibrosis. Sionna represents a specialized player in the rare disease therapeutics space, dedicating its resources entirely to addressing the underlying molecular defects that cause cystic fibrosis rather than just managing symptoms.